Diagnostic performance of HE4 and ROMA among Chinese women
- 15 October 2019
- journal article
- research article
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 500, 42-46
- https://doi.org/10.1016/j.cca.2019.10.002
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesTumor Biology, 2011
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic massAmerican Journal of Obstetrics and Gynecology, 2010
- Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal massGynecologic Oncology, 2010
- Current state of biomarker development for clinical application in epithelial ovarian cancerGynecologic Oncology, 2010
- HE4 as a biomarker for ovarian and endometrial cancer managementExpert Review of Molecular Diagnostics, 2009
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 studyThe Lancet Oncology, 2007
- Diagnosis and Management of Epithelial Ovarian CancerObstetrics & Gynecology, 2006